MD Anderson, Flagship startup partner to design and test cancer drugs made with generative AI

Ryan Cross

Senior Science Correspondent

Generate Biomedicines, a startup founded by the life science investment company Flagship Pioneering, has partnered with the University of Texas MD Anderson Cancer Center to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MD Anderson, Flagship startup partner to design and test cancer drugs made with generative AI

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

MD An­der­son, Flag­ship start­up part­ner to de­sign and test can­cer drugs made with gen­er­a­tive AI

Senior Science Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

MD Anderson, Flagship startup partner to design and test cancer drugs made with generative AI